{"id":995812,"date":"2026-08-17T07:15:11","date_gmt":"2026-08-17T11:15:11","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/tagrisso-osimertinib-plus-savolitinib-demonstrated-statistically-significant-and-clinically-meaningful-improvements-in-progression-free-and-overall-survival-in-met-driven-egfr-mutated-lung-can\/"},"modified":"2026-08-17T07:15:11","modified_gmt":"2026-08-17T11:15:11","slug":"tagrisso-osimertinib-plus-savolitinib-demonstrated-statistically-significant-and-clinically-meaningful-improvements-in-progression-free-and-overall-survival-in-met-driven-egfr-mutated-lung-can","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/tagrisso-osimertinib-plus-savolitinib-demonstrated-statistically-significant-and-clinically-meaningful-improvements-in-progression-free-and-overall-survival-in-met-driven-egfr-mutated-lung-can\/","title":{"rendered":"TAGRISSO\u00ae (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwalignr { text-align: right; list-style-position: inside }\n.bwlistcircle { list-style-type: circle }\n.bwlistdecimal { list-style-type: decimal }\n.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>TAGRISSO\u00ae (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO<\/b><\/p>\n<p class=\"bwalignc\"><b><i>First global Phase III trial to show significant progression-free and overall survival benefits in this setting<\/i><\/b><\/p>\n<p class=\"bwalignc\"><b><i>SAFFRON trial results reinforce TAGRISSO as the backbone therapy across EGFRm lung cancer<\/i><\/b><\/p>\n<p>WILMINGTON, Del.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nPositive high-level results from the SAFFRON Phase III trial showed TAGRISSO<sup>\u00ae<\/sup> (osimertinib) plus savolitinib demonstrated a statistically significant and clinically meaningful improvement in both progression-free survival (PFS) and overall survival (OS) versus doublet platinum-based chemotherapy in patients with epidermal growth factor receptor-mutated (<i>EGFR<\/i>m) non-small cell lung cancer (NSCLC). Patients in the trial had tumors with high levels of MET overexpression or amplification and had progressed on prior treatment with TAGRISSO.<\/p>\n<p>\nThird-generation <i>EGFR<\/i>-tyrosine kinase inhibitors (TKIs) have significantly improved outcomes for patients with <i>EGFR<\/i>m NSCLC.<sup>1<\/sup> However, one in three patients\u2019 tumors will develop MET overexpression or amplification, one of the most common mechanisms of resistance on third-generation <i>EGFR<\/i>-TKIs.<sup>1-2<\/sup> MET-driven resistance is associated with poor prognosis, and there is a significant unmet need for effective and well-tolerated treatment options in later-line settings.<sup>2<\/sup><\/p>\n<p>\nProfessor Shun Lu, Director of Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiaotong Tong University School of Medicine and principal investigator of the trial, said: \u201cThese exciting results from SAFFRON represent a critical advance for patients with <i>EGFR<\/i>-mutated non-small cell lung cancer experiencing MET-driven resistance after osimertinib, a population with poor outcomes and no biomarker-directed treatment options available that are oral and well-tolerated. MET is one of the most common drivers of progression on targeted therapy in this setting, and these data underscore the potential impact of this novel osimertinib plus savolitinib combination and the urgency of MET testing to inform treatment decisions.\u201d<\/p>\n<p>\nSusan Galbraith, Executive Vice President, Oncology Haematology R&amp;D, AstraZeneca, said: \u201cThese data demonstrate the clear benefit of adding savolitinib to backbone therapy TAGRISSO to address MET overexpression or amplification while maintaining <i>EGFR<\/i> suppression<i>. <\/i>By combining savolitinib and TAGRISSO, with its established efficacy, safety profile and central nervous system protection<i>, <\/i>we<i \/>aim to deliver the first biomarker-directed, all-oral option in this setting to patients across the globe. This further strengthens our leadership in <i>EGFR<\/i>-mutated lung cancer, reinforcing our strategy to improve patient outcomes across stages and through lines of therapy with novel combinations.\u201d<\/p>\n<p>\nWeiguo Su, Chief Executive Officer and Chief Scientific Officer of HUTCHMED, said: \u201cOvercoming MET-driven resistance after <i>EGFR<\/i>-TKI therapy has been a long-standing challenge in clinical practice. The SAFFRON global study further reinforces the robust efficacy previously demonstrated in the SACHI Phase III trial that supported approval in China, with the results providing clear evidence to support global registrations of the TAGRISSO and savolitinib combination. We are grateful to everyone who supported this trial. Together with AstraZeneca, we look forward to potentially bringing this landmark treatment to patients around the world.\u201d<\/p>\n<p>\nThe safety profile for TAGRISSO plus savolitinib was consistent with the known profiles of each medicine, and there were no new safety findings. These data will be presented at a forthcoming medical meeting and shared with global regulatory authorities.<\/p>\n<p>\nTAGRISSO plus savolitinib is approved in China for patients with locally advanced or metastatic <i>EGFR<\/i>m NSCLC with MET amplification after disease progression on <i>EGFR<\/i>-TKI therapy based on the SACHI Phase III trial.<\/p>\n<p>\nSavolitinib is being jointly developed by AstraZeneca and HUTCHMED and commercialized by AstraZeneca.<\/p>\n<p><b>IMPORTANT SAFETY INFORMATION FOR TAGRISSO<sup>\u00ae<\/sup> (osimertinib)<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nThere are no contraindications for TAGRISSO<\/p>\n<\/li>\n<li>\nTAGRISSO can cause severe and fatal interstitial lung disease (ILD)\/pneumonitis. ILD\/pneumonitis occurred in 4% of the 1813 patients treated with TAGRISSO monotherapy who had not received recent definitive chemoradiation therapy; 0.4% of cases were fatal<\/p>\n<\/li>\n<\/ul>\n<p><b>ILD\/Pneumonitis with TAGRISSO in combination with Pemetrexed and Platinum-based Chemotherapy:<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nIn the FLAURA2 study, ILD\/pneumonitis occurred in 3.3% of the 276 patients who received TAGRISSO in combination with pemetrexed and platinum-based chemotherapy; 0.4% of cases were fatal<\/p>\n<\/li>\n<\/ul>\n<p><b>ILD\/Pneumonitis Following Definitive Platinum-based Chemoradiation Therapy (CRT):<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nIn the LAURA study, following definitive platinum-based CRT, ILD\/pneumonitis including radiation pneumonitis, occurred in 80 of the 143 patients (56%) who received TAGRISSO monotherapy and 28 of the 73 patients (38%) who received placebo. There was one fatal case (0.7%), 3.5% Grade 3, 34% Grade 2, and 18% Grade 1 adverse reactions of ILD\/pneumonitis in TAGRISSO-treated patients. For TAGRISSO-treated patients, ILD\/pneumonitis led to permanent discontinuation of TAGRISSO in 7% of patients and dosage interruptions of TAGRISSO in 35% of patients. Among the 46 patients who were rechallenged with TAGRISSO, 11% had recurrence of ILD\/pneumonitis. In the 80 TAGRISSO-treated patients, ILD\/pneumonitis resolved in 40%, resolved with sequelae in 1.3%, were resolving in 16%, did not resolve in 41%, and resulted in death in 1.3%<\/p>\n<\/li>\n<\/ul>\n<p>\nFor patients receiving TAGRISSO who have not received recent definitive platinum-based CRT, withhold TAGRISSO and promptly investigate for ILD in patients who present with worsening of respiratory symptoms which may be indicative of ILD (e.g., dyspnea, cough, and fever). Permanently discontinue TAGRISSO if ILD\/pneumonitis is confirmed. For patients who have received recent definitive platinum- based CRT with Grade 1 ILD\/pneumonitis, continue TAGRISSO or interrupt and restart, as appropriate. Permanently discontinue TAGRISSO in patients diagnosed with Grade \u22652 ILD\/pneumonitis<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nTAGRISSO can cause heart rate-corrected QT (QTc) interval prolongation. Of the 1813 TAGRISSO monotherapy-treated patients in clinical trials, 1.1% were found to have a QTc &gt;500 msec, and 4.3% of patients had an increase from baseline QTc &gt;60 msec. Of the 276 patients treated with TAGRISSO in combination with pemetrexed and platinum-based chemotherapy in the FLAURA2 study, 1.8% were found to have a QTc &gt;500 msec, and 10.5% of patients had an increase from baseline QTc &gt;60 msec. No QTc-related arrhythmias were reported. Clinical trials of TAGRISSO did not enroll patients with baseline QTc of &gt;470 msec. Conduct periodic monitoring with ECGs and electrolytes in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those who are taking medications known to prolong the QTc interval. Permanently discontinue TAGRISSO in patients who develop QTc interval prolongation with signs\/symptoms of life-threatening arrhythmia<\/p>\n<\/li>\n<li>\nTAGRISSO can cause cardiomyopathy, including cardiac failure, chronic cardiac failure, congestive heart failure, pulmonary edema or decreased ejection fraction. Cardiomyopathy occurred in 3.8% of the 1813 TAGRISSO-treated patients; 0.1% of cardiomyopathy cases were fatal. In the FLAURA2 study, cardiomyopathy occurred in 9% of the 276 patients who received TAGRISSO in combination with pemetrexed and platinum-based chemotherapy; 1.1% of cardiomyopathy cases were fatal. A decline in left ventricular ejection fraction (LVEF) \u226510% from baseline and to &lt;50% LVEF occurred in 4.2% of 1557 patients who had baseline and at least one follow-up LVEF assessment. In the ADAURA study, 1.5% (5\/325) of TAGRISSO-treated patients experienced LVEF decreases \u226510% from baseline and a drop to &lt;50%. In the LAURA study, following platinum-based CRT, 3% (4\/135) of TAGRISSO-treated patients and no placebo-treated patients experienced LVEF decreases \u226510% and a drop to &lt;50%. In the FLAURA2 study, 8% (21\/262) of patients treated with TAGRISSO in combination with pemetrexed and platinum- based chemotherapy, who had baseline and at least one follow-up LVEF assessment, experienced LVEF decreases \u226510% and a drop to &lt;50%. For patients receiving TAGRISSO monotherapy, conduct cardiac monitoring in patients with cardiac risk factors, including assessment of LVEF at baseline and during treatment. For patients receiving TAGRISSO in combination with pemetrexed and platinum-based chemotherapy, conduct cardiac monitoring in all patients, including assessment of LVEF at baseline and during treatment. Assess LVEF in patients who develop relevant cardiac signs or symptoms during treatment. For symptomatic congestive heart failure, permanently discontinue TAGRISSO<\/p>\n<\/li>\n<li>\nKeratitis was reported in 0.6% of 1813 patients treated with TAGRISSO monotherapy in clinical trials. Promptly refer patients with signs and symptoms suggestive of keratitis (such as eye inflammation, lacrimation, light sensitivity, blurred vision, eye pain and\/or red eye) to an ophthalmologist<\/p>\n<\/li>\n<li>\nPostmarketing cases consistent with erythema multiforme major (EMM), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported in patients receiving TAGRISSO. Withhold TAGRISSO if EMM, SJS, or TEN is suspected and permanently discontinue if confirmed<\/p>\n<\/li>\n<li>\nPostmarketing cases of cutaneous vasculitis including leukocytoclastic vasculitis, urticarial vasculitis, and IgA vasculitis have been reported in patients receiving TAGRISSO. Withhold TAGRISSO if cutaneous vasculitis is suspected, evaluate for systemic involvement, and consider dermatology consultation. If no other etiology can be identified, consider permanent discontinuation of TAGRISSO based on severity<\/p>\n<\/li>\n<li>\nAplastic anemia has been reported in TAGRISSO-treated patients in clinical trials (0.06% of 1813) and postmarketing. Some cases had a fatal outcome. Inform patients of the signs and symptoms of aplastic anemia including but not limited to, new or persistent fevers, bruising, bleeding, and pallor. If aplastic anemia is suspected, withhold TAGRISSO and obtain a hematology consultation. If aplastic anemia is confirmed, permanently discontinue TAGRISSO. Perform complete blood count with differential before starting TAGRISSO, periodically throughout treatment, and more frequently if indicated<\/p>\n<\/li>\n<li>\nVerify pregnancy status of females of reproductive potential prior to initiating TAGRISSO. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with TAGRISSO and for 6 weeks after the last dose. Advise males with female partners of reproductive potential to use effective contraception for 4 months after the last dose<\/p>\n<\/li>\n<li>\nBecause of the potential for serious adverse reactions in breastfed infants from TAGRISSO, women should not breastfeed during treatment with TAGRISSO and for 2 weeks after the last dose<\/p>\n<\/li>\n<li>\nMost common (\u226520%) adverse reactions, including laboratory abnormalities, were:<\/p>\n<ul class=\"bwlistcircle\">\n<li>\nTAGRISSO monotherapy: leukopenia, lymphopenia, thrombocytopenia, anemia, diarrhea, rash, musculoskeletal pain, neutropenia, nail toxicity, dry skin, stomatitis, and fatigue<\/p>\n<\/li>\n<li>\nTAGRISSO monotherapy following platinum-based chemoradiation therapy: lymphopenia, leukopenia, ILD\/pneumonitis, thrombocytopenia, neutropenia, rash, diarrhea, nail toxicity, musculoskeletal pain, cough and COVID-19<\/p>\n<\/li>\n<li>\nTAGRISSO in combination with pemetrexed and platinum-based chemotherapy: leukopenia, thrombocytopenia, neutropenia, lymphopenia, rash, diarrhea, stomatitis, nail toxicity, dry skin, and increased blood creatinine<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><b>INDICATIONS<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nTAGRISSO is indicated as adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test<\/p>\n<\/li>\n<li>\nTAGRISSO is indicated for the treatment of adult patients with locally advanced, unresectable (stage III) NSCLC whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy and whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test<\/p>\n<\/li>\n<li>\nTAGRISSO is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test<\/p>\n<\/li>\n<li>\nTAGRISSO is indicated in combination with pemetrexed and platinum-based chemotherapy, for the first-line treatment of adult patients with locally advanced or metastatic NSCLC whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test<\/p>\n<\/li>\n<li>\nTAGRISSO is indicated for the treatment of adult patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive NSCLC, as detected by an FDA-approved test, whose disease has progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy<\/p>\n<\/li>\n<\/ul>\n<p><b>Please see complete <\/b><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fdrd9vrdh9yh09.cloudfront.net%2F50fd68b9-106b-4550-b5d0-12b045f8b184%2F52503580-1192-44f7-a05e-5743159ed19b%2F52503580-1192-44f7-a05e-5743159ed19b_viewable_rendition__v.pdf&amp;esheet=54589855&amp;newsitemid=20260817534800&amp;lan=en-US&amp;anchor=Prescribing+Information&amp;index=1&amp;md5=9d4e106ce71877ce59b8f5add3208550\"><b>Prescribing Information<\/b><\/a><b>, including <\/b><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fdrd9vrdh9yh09.cloudfront.net%2F50fd68b9-106b-4550-b5d0-12b045f8b184%2F52503580-1192-44f7-a05e-5743159ed19b%2F52503580-1192-44f7-a05e-5743159ed19b_pi_med_guide_rendition__c.pdf&amp;esheet=54589855&amp;newsitemid=20260817534800&amp;lan=en-US&amp;anchor=Patient+Information&amp;index=2&amp;md5=40687c6a6ee83c31ad26ec7a55b91d67\"><b>Patient Information<\/b><\/a><b> for TAGRISSO.<\/b><\/p>\n<p><b>Notes<\/b><\/p>\n<p><b>NSCLC and MET aberrations<br \/>\n<br \/><\/b>Lung cancer is the leading cause of cancer death globally, accounting for almost one in four (23%) cancer deaths.<sup>3<\/sup> Lung cancer is broadly split into NSCLC and small cell lung cancer, with 80-85% of patients diagnosed with NSCLC.<sup>4<\/sup> Approximately 75% of NSCLC patients are diagnosed with advanced disease.<sup>5<\/sup> Additionally, about 10-15% of NSCLC patients in the US and Europe, and 30-40% of patients in Asia, have <i>EGFR<\/i>m NSCLC.<sup>\u200b6-8<\/sup><\/p>\n<p>\nMET is a tyrosine kinase receptor that has an essential role in normal cell development.<sup>9<\/sup> MET overexpression or amplification can lead to tumor growth and the metastatic progression of cancer cells.<sup>9-10<\/sup> An estimated 34% of tumors will develop high levels of MET overexpression or amplification after progression on a third-generation <i>EGFR<\/i> TKI.<sup>1<\/sup> \u200b<\/p>\n<p><b>SAFFRON<br \/>\n<br \/><\/b>SAFFRON is a randomized, open-label, multi-center, global Phase III trial studying the efficacy of savolitinib (300 mg twice daily) added to TAGRISSO (80 mg once daily) versus doublet platinum-based chemotherapy in 338 patients with <i>EGFR<\/i>m, locally advanced or metastatic NSCLC with MET overexpression or amplification whose disease progressed following 1st- or 2nd-line treatment with TAGRISSO. The trial enrolled patients in 230 centers across 29 countries, including in North America, Europe, South America and Asia. The primary endpoint is PFS and key secondary endpoints include OS and objective response rate.<\/p>\n<p>\nPatients were prospectively selected for SAFFRON using the high MET level cut-offs identified in the SAVANNAH Phase II trial.\u200b In SAVANNAH, MET overexpression or amplification levels were determined by two tests: immunohistochemistry (IHC), which detects if cancer cells have a particular protein or marker on their surface, and fluorescence in situ hybridization (FISH), which detects a specific DNA sequence from cancer cells.<\/p>\n<p><b>Savolitinib<br \/>\n<br \/><\/b>Savolitinib is an oral, potent and highly selective MET-TKI that has demonstrated clinical activity in advanced solid tumors. It blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations (such as exon 14 skipping alterations or other point mutations), gene amplification or protein overexpression.<\/p>\n<p>\nSavolitinib is approved in China for the treatment of adult patients with locally advanced or metastatic NSCLC with MET exon 14 skipping alteration, representing the first selective MET inhibitor approved in China. Savolitinib also received a conditional approval in China for the treatment of patients with locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma with MET amplification who have failed at least two prior systemic treatments.<\/p>\n<p>\nSavolitinib in combination with TAGRISSO is approved in China for patients with locally advanced or metastatic <i>EGFR<\/i>m-positive non-squamous NSCLC with MET amplification after disease progression on EGFR-TKI therapy based on the SACHI Phase III trial. The combination was also granted a temporary authorization in Switzerland for the treatment of patients with locally advanced or metastatic <i>EGFR<\/i>m NSCLC and high levels of MET overexpression or amplification who progressed on prior treatment with TAGRISSO<i>. <\/i>This was based on results from the global SAVANNAH Phase II trial.<\/p>\n<p><b>TAGRISSO<sup>\u00ae<\/sup> (osimertinib)<br \/>\n<br \/><\/b>TAGRISSO<sup>\u00ae<\/sup> (osimertinib) is a third-generation, irreversible <i>EGFR<\/i>-TKI with proven clinical activity in NSCLC, including the treatment of central nervous system metastases. TAGRISSO (40 mg and 80 mg QD oral tablets) has been used to treat more than one million patients across its indications worldwide and AstraZeneca continues to explore TAGRISSO as a treatment for patients across multiple stages of <i>EGFR<\/i>m NSCLC.<\/p>\n<p>\nTAGRISSO is approved as monotherapy in more than 120 countries including the US, EU, China and Japan. Approved indications include for 1st-line treatment of patients with locally advanced or metastatic <i>EGFR<\/i>m NSCLC, locally advanced or metastatic <i>EGFR<\/i> T790M mutation-positive NSCLC, adjuvant treatment of early-stage <i>EGFR<\/i>m NSCLC and locally advanced, unresectable NSCLC following platinum-based chemoradiation therapy. TAGRISSO is also approved in combination with chemotherapy in more than 80 countries, including the US, EU, China and Japan, for 1st-line treatment of patients with locally advanced or metastatic <i>EGFR<\/i>m NSCLC.<\/p>\n<p>\nThere is an extensive body of evidence supporting the use of TAGRISSO in <i>EGFR<\/i>m NSCLC, and it is the only targeted therapy shown to improve patient outcomes across all stages of the disease.<\/p>\n<p>\nIn late-stage disease, TAGRISSO demonstrated improved outcomes as monotherapy in the <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.astrazeneca.com%2Fmedia-centre%2Fpress-releases%2F2019%2Ftagrisso-significantly-improves-overall-survival-in-the-phase-iii-flaura-trial-for-1st-line-egfr-mutated-non-small-cell-lung-cancer-09082019.html&amp;esheet=54589855&amp;newsitemid=20260817534800&amp;lan=en-US&amp;anchor=FLAURA&amp;index=3&amp;md5=eaa8ac8213d7ea97f142b3c01fe929b3\">FLAURA<\/a> Phase III trial and in combination with chemotherapy in the <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.astrazeneca-us.com%2Fmedia%2Fpress-releases%2F2023%2Ftagrisso-osimertinib-plus-chemotherapy-demonstrated-strong-improvement-in-progression-free-survival-for-patients-with-egfr-mutated-advanced-lung-cancer-in-flaura2-phase-iii-trial-05172023.html&amp;esheet=54589855&amp;newsitemid=20260817534800&amp;lan=en-US&amp;anchor=FLAURA2&amp;index=4&amp;md5=d84494f41d69a0e2dbdf8303fdeb5fb0\">FLAURA2<\/a> Phase III trial. TAGRISSO is also being investigated in this setting in combination with datopotamab deruxtecan-dlnk in the <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06350097&amp;esheet=54589855&amp;newsitemid=20260817534800&amp;lan=en-US&amp;anchor=TROPION-Lung14&amp;index=5&amp;md5=412d592672eab733d2a60c4b6e3bc66b\">TROPION-Lung14<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06417814&amp;esheet=54589855&amp;newsitemid=20260817534800&amp;lan=en-US&amp;anchor=TROPION-Lung15&amp;index=6&amp;md5=e0c2b85f77fffc0ceff7ddefdb417f35\">TROPION-Lung15<\/a> Phase III trials.<\/p>\n<p>\nTAGRISSO also showed improved outcomes in early-stage disease in the NeoADAURA and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.astrazeneca-us.com%2Fmedia%2Fpress-releases%2F2023%2Ftagrisso-osimertinib-demonstrated-strong-overall-survival-benefit-in-the-adaura-phase-iii-trial-for-adjuvant-treatment-of-patients-with-early-stage-egfr-mutated-lung-cancer-03092023.html&amp;esheet=54589855&amp;newsitemid=20260817534800&amp;lan=en-US&amp;anchor=ADAURA&amp;index=7&amp;md5=2201ef9df6b846883b436b14d0b2ed1a\">ADAURA<\/a> Phase III trials and in locally advanced stages in the <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.astrazeneca-us.com%2Fmedia%2Fpress-releases%2F2024%2Ftagrisso-osimertinib-demonstrated-overwhelming-efficacy-benefit-for-patients-with-unresectable-stage-iii-egfr-mutated-lung-cancer-in-laura-phase-iii-trial.html&amp;esheet=54589855&amp;newsitemid=20260817534800&amp;lan=en-US&amp;anchor=LAURA&amp;index=8&amp;md5=1ac5f26012f4e138fb1c8b1c536acde9\">LAURA<\/a> Phase III trial. As part of AstraZeneca\u2019s ongoing commitment to treating patients as early as possible in lung cancer, TAGRISSO is also being investigated in the early-stage adjuvant resectable setting in the ADAURA2 Phase III trial.<\/p>\n<p><b>AstraZeneca in lung cancer<br \/>\n<br \/><\/b>AstraZeneca is working to bring patients with lung cancer closer to cure through the detection and treatment of early-stage disease, while also pushing the boundaries of science to improve outcomes in the resistant and advanced settings. By defining new therapeutic targets and investigating innovative approaches, the Company aims to match medicines to the patients who can benefit most.<\/p>\n<p>\nThe Company\u2019s comprehensive portfolio includes leading lung cancer medicines and the next wave of innovations, including TAGRISSO and gefitinib;<i \/>durvalumab and tremelimumab-actl; fam-trastuzumab deruxtecan-nxki and datopotamab deruxtecan-dlnk<i \/>in collaboration with Daiichi Sankyo; savolitinib in collaboration with HUTCHMED; as well as a pipeline of potential new medicines and combinations across diverse mechanisms of action.<\/p>\n<p>\nAstraZeneca is a founding member of the Lung Ambition Alliance, a global coalition working to accelerate innovation and deliver meaningful improvements for people with lung cancer, including and beyond treatment.<\/p>\n<p><b>AstraZeneca in oncology<br \/>\n<br \/><\/b>AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients.<\/p>\n<p>\nThe Company&#8217;s focus is on some of the most challenging cancers. It is through persistent innovation that AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyze changes in the practice of medicine and transform the patient experience.<\/p>\n<p>\nAstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.<\/p>\n<p><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.astrazeneca-us.com%2F&amp;esheet=54589855&amp;newsitemid=20260817534800&amp;lan=en-US&amp;anchor=AstraZeneca&amp;index=9&amp;md5=3bee5a0683743509c9794bef8b844c31\"><b>AstraZeneca<br \/>\n<\/b><\/a><b><br \/><\/b>AstraZeneca (LSE\/STO\/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal &amp; Metabolism, and Respiratory &amp; Immunology. Based in Cambridge, UK, AstraZeneca\u2019s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.astrazeneca-us.com%2F&amp;esheet=54589855&amp;newsitemid=20260817534800&amp;lan=en-US&amp;anchor=astrazeneca-us.com&amp;index=10&amp;md5=493e96840b0abb62f9e738e03889d46e\">astrazeneca-us.com<\/a> and follow the Company on social media <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fastrazeneca&amp;esheet=54589855&amp;newsitemid=20260817534800&amp;lan=en-US&amp;anchor=%40AstraZeneca&amp;index=11&amp;md5=2d7d704886b7ad45ec80edd6a90fdeeb\">@AstraZeneca<\/a>.<\/p>\n<p><b>References<\/b><\/p>\n<ol class=\"bwlistdecimal\">\n<li>\nDe Marinis F, <i>et al<\/i>. Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and\/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study. <i>Ann Oncol<\/i>. 2025;36(8):920-933.<\/p>\n<\/li>\n<li>\nBar J, <i>et al<\/i>. Prevalence, molecular characterization, and prognosis of c-Met protein overexpression in a real-world cohort of patients with non-squamous non-small cell lung cancer. <i>Acta Oncol<\/i>. 2025;64:1544-1553.<\/p>\n<\/li>\n<li>\nWorld Health Organization. International Agency for Research on Cancer. Lung Fact Sheet. Available at: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fgco.iarc.who.int%2Fmedia%2Fglobocan%2Ffactsheets%2Fcancers%2F15-trachea-bronchus-and-lung-fact-sheet.pdf&amp;esheet=54589855&amp;newsitemid=20260817534800&amp;lan=en-US&amp;anchor=https%3A%2F%2Fgco.iarc.who.int%2Fmedia%2Fglobocan%2Ffactsheets%2Fcancers%2F15-trachea-bronchus-and-lung-fact-sheet.pdf&amp;index=12&amp;md5=2fa3d714dfa53a4ab32ca0e979f27003\">https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/cancers\/15-trachea-bronchus-and-lung-fact-sheet.pdf<\/a>. Accessed August 2026.<\/p>\n<\/li>\n<li>\nAmerican Cancer Society. What Is Lung Cancer? Available at: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cancer.org%2Fcancer%2Ftypes%2Flung-cancer%2Fabout%2Fwhat-is.html&amp;esheet=54589855&amp;newsitemid=20260817534800&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.cancer.org%2Fcancer%2Ftypes%2Flung-cancer%2Fabout%2Fwhat-is.html&amp;index=13&amp;md5=8e14837fe8d440993a7d6384045caa25\">https:\/\/www.cancer.org\/cancer\/types\/lung-cancer\/about\/what-is.html<\/a>. Accessed August 2026.<\/p>\n<\/li>\n<li>\nChen HJ,<i> et al<\/i>. Long-term survival of advanced lung adenocarcinoma by maintenance chemotherapy followed by EGFR-TKI. <i>Medicine<\/i>. 2021;100(6):e24688.<\/p>\n<\/li>\n<li>\nSzumera-Cie\u0107kiewicz A, <i>et al<\/i>. EGFR Mutation Testing on Cytological and Histological Samples in Non-Small Cell Lung Cancer: a Polish, Single Institution Study and Systematic Review of European Incidence. <i>Int J Clin Exp Pathol<\/i>. 2013;6:2800-2812.<\/p>\n<\/li>\n<li>\nKeedy VL, <i>et al<\/i>. American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients with Advanced Non-Small-Cell Lung Cancer Considering First- Line EGFR Tyrosine Kinase Inhibitor Therapy. <i>J Clin Oncol<\/i>. 2011;29:2121-2127.<\/p>\n<\/li>\n<li>\nEllison G, <i>et al<\/i>. EGFR Mutation Testing in Lung Cancer: a Review of Available Methods and Their Use for Analysis of Tumour Tissue and Cytology Samples. <i>J Clin Pathol<\/i>. 2013;66:79-89.<\/p>\n<\/li>\n<li>\nUchikawa E, <i>et al<\/i>. Structural basis of the activation of c-MET receptor. <i>Nat Commun<\/i>. 2021;12(4074)<\/p>\n<\/li>\n<li>\nWang Q, <i>et al<\/i>. MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer. <i>J Hematol Oncol<\/i>. 2019;63.<\/p>\n<\/li>\n<\/ol>\n<p class=\"bwalignr\">\nUS-115297 Last Updated 8\/26<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260817534800r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260817534800\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260817534800\/en\/<\/a><\/span><\/p>\n<p><b>Media Inquiries<br \/>\n<br \/><\/b>Lauren-Jei McCarthy\u00a0+1 347 918 7001<br \/>\n<br \/>US Media Mailbox: <a rel=\"nofollow\" href=\"mailto:usmediateam@astrazeneca.com\">usmediateam@astrazeneca.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Delaware United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Oncology Health Clinical Trials Research Science Pharmaceutical Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260817534800\/en\/2301168\/3\/original.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>TAGRISSO\u00ae (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO First global Phase III trial to show significant progression-free and overall survival benefits in this setting SAFFRON trial results reinforce TAGRISSO as the backbone therapy across EGFRm lung cancer WILMINGTON, Del.&#8211;(BUSINESS WIRE)&#8211; Positive high-level results from the SAFFRON Phase III trial showed TAGRISSO\u00ae (osimertinib) plus savolitinib demonstrated a statistically significant and clinically meaningful improvement in both progression-free survival (PFS) and overall survival (OS) versus doublet platinum-based chemotherapy in patients with epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). Patients in the trial had tumors with high levels of MET overexpression or amplification and &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tagrisso-osimertinib-plus-savolitinib-demonstrated-statistically-significant-and-clinically-meaningful-improvements-in-progression-free-and-overall-survival-in-met-driven-egfr-mutated-lung-can\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;TAGRISSO\u00ae (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-995812","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>TAGRISSO\u00ae (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tagrisso-osimertinib-plus-savolitinib-demonstrated-statistically-significant-and-clinically-meaningful-improvements-in-progression-free-and-overall-survival-in-met-driven-egfr-mutated-lung-can\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"TAGRISSO\u00ae (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"TAGRISSO\u00ae (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO First global Phase III trial to show significant progression-free and overall survival benefits in this setting SAFFRON trial results reinforce TAGRISSO as the backbone therapy across EGFRm lung cancer WILMINGTON, Del.&#8211;(BUSINESS WIRE)&#8211; Positive high-level results from the SAFFRON Phase III trial showed TAGRISSO\u00ae (osimertinib) plus savolitinib demonstrated a statistically significant and clinically meaningful improvement in both progression-free survival (PFS) and overall survival (OS) versus doublet platinum-based chemotherapy in patients with epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). Patients in the trial had tumors with high levels of MET overexpression or amplification and &hellip; Continue reading &quot;TAGRISSO\u00ae (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/tagrisso-osimertinib-plus-savolitinib-demonstrated-statistically-significant-and-clinically-meaningful-improvements-in-progression-free-and-overall-survival-in-met-driven-egfr-mutated-lung-can\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-17T11:15:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260817534800r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"16 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tagrisso-osimertinib-plus-savolitinib-demonstrated-statistically-significant-and-clinically-meaningful-improvements-in-progression-free-and-overall-survival-in-met-driven-egfr-mutated-lung-can\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tagrisso-osimertinib-plus-savolitinib-demonstrated-statistically-significant-and-clinically-meaningful-improvements-in-progression-free-and-overall-survival-in-met-driven-egfr-mutated-lung-can\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"TAGRISSO\u00ae (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO\",\"datePublished\":\"2026-08-17T11:15:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tagrisso-osimertinib-plus-savolitinib-demonstrated-statistically-significant-and-clinically-meaningful-improvements-in-progression-free-and-overall-survival-in-met-driven-egfr-mutated-lung-can\\\/\"},\"wordCount\":3212,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tagrisso-osimertinib-plus-savolitinib-demonstrated-statistically-significant-and-clinically-meaningful-improvements-in-progression-free-and-overall-survival-in-met-driven-egfr-mutated-lung-can\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260817534800r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tagrisso-osimertinib-plus-savolitinib-demonstrated-statistically-significant-and-clinically-meaningful-improvements-in-progression-free-and-overall-survival-in-met-driven-egfr-mutated-lung-can\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tagrisso-osimertinib-plus-savolitinib-demonstrated-statistically-significant-and-clinically-meaningful-improvements-in-progression-free-and-overall-survival-in-met-driven-egfr-mutated-lung-can\\\/\",\"name\":\"TAGRISSO\u00ae (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tagrisso-osimertinib-plus-savolitinib-demonstrated-statistically-significant-and-clinically-meaningful-improvements-in-progression-free-and-overall-survival-in-met-driven-egfr-mutated-lung-can\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tagrisso-osimertinib-plus-savolitinib-demonstrated-statistically-significant-and-clinically-meaningful-improvements-in-progression-free-and-overall-survival-in-met-driven-egfr-mutated-lung-can\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260817534800r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-08-17T11:15:11+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tagrisso-osimertinib-plus-savolitinib-demonstrated-statistically-significant-and-clinically-meaningful-improvements-in-progression-free-and-overall-survival-in-met-driven-egfr-mutated-lung-can\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tagrisso-osimertinib-plus-savolitinib-demonstrated-statistically-significant-and-clinically-meaningful-improvements-in-progression-free-and-overall-survival-in-met-driven-egfr-mutated-lung-can\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tagrisso-osimertinib-plus-savolitinib-demonstrated-statistically-significant-and-clinically-meaningful-improvements-in-progression-free-and-overall-survival-in-met-driven-egfr-mutated-lung-can\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260817534800r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260817534800r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tagrisso-osimertinib-plus-savolitinib-demonstrated-statistically-significant-and-clinically-meaningful-improvements-in-progression-free-and-overall-survival-in-met-driven-egfr-mutated-lung-can\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"TAGRISSO\u00ae (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"TAGRISSO\u00ae (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/tagrisso-osimertinib-plus-savolitinib-demonstrated-statistically-significant-and-clinically-meaningful-improvements-in-progression-free-and-overall-survival-in-met-driven-egfr-mutated-lung-can\/","og_locale":"en_US","og_type":"article","og_title":"TAGRISSO\u00ae (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO - Market Newsdesk","og_description":"TAGRISSO\u00ae (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO First global Phase III trial to show significant progression-free and overall survival benefits in this setting SAFFRON trial results reinforce TAGRISSO as the backbone therapy across EGFRm lung cancer WILMINGTON, Del.&#8211;(BUSINESS WIRE)&#8211; Positive high-level results from the SAFFRON Phase III trial showed TAGRISSO\u00ae (osimertinib) plus savolitinib demonstrated a statistically significant and clinically meaningful improvement in both progression-free survival (PFS) and overall survival (OS) versus doublet platinum-based chemotherapy in patients with epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). Patients in the trial had tumors with high levels of MET overexpression or amplification and &hellip; Continue reading \"TAGRISSO\u00ae (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/tagrisso-osimertinib-plus-savolitinib-demonstrated-statistically-significant-and-clinically-meaningful-improvements-in-progression-free-and-overall-survival-in-met-driven-egfr-mutated-lung-can\/","og_site_name":"Market Newsdesk","article_published_time":"2026-08-17T11:15:11+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260817534800r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"16 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tagrisso-osimertinib-plus-savolitinib-demonstrated-statistically-significant-and-clinically-meaningful-improvements-in-progression-free-and-overall-survival-in-met-driven-egfr-mutated-lung-can\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tagrisso-osimertinib-plus-savolitinib-demonstrated-statistically-significant-and-clinically-meaningful-improvements-in-progression-free-and-overall-survival-in-met-driven-egfr-mutated-lung-can\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"TAGRISSO\u00ae (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO","datePublished":"2026-08-17T11:15:11+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tagrisso-osimertinib-plus-savolitinib-demonstrated-statistically-significant-and-clinically-meaningful-improvements-in-progression-free-and-overall-survival-in-met-driven-egfr-mutated-lung-can\/"},"wordCount":3212,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tagrisso-osimertinib-plus-savolitinib-demonstrated-statistically-significant-and-clinically-meaningful-improvements-in-progression-free-and-overall-survival-in-met-driven-egfr-mutated-lung-can\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260817534800r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tagrisso-osimertinib-plus-savolitinib-demonstrated-statistically-significant-and-clinically-meaningful-improvements-in-progression-free-and-overall-survival-in-met-driven-egfr-mutated-lung-can\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/tagrisso-osimertinib-plus-savolitinib-demonstrated-statistically-significant-and-clinically-meaningful-improvements-in-progression-free-and-overall-survival-in-met-driven-egfr-mutated-lung-can\/","name":"TAGRISSO\u00ae (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tagrisso-osimertinib-plus-savolitinib-demonstrated-statistically-significant-and-clinically-meaningful-improvements-in-progression-free-and-overall-survival-in-met-driven-egfr-mutated-lung-can\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tagrisso-osimertinib-plus-savolitinib-demonstrated-statistically-significant-and-clinically-meaningful-improvements-in-progression-free-and-overall-survival-in-met-driven-egfr-mutated-lung-can\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260817534800r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-08-17T11:15:11+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tagrisso-osimertinib-plus-savolitinib-demonstrated-statistically-significant-and-clinically-meaningful-improvements-in-progression-free-and-overall-survival-in-met-driven-egfr-mutated-lung-can\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/tagrisso-osimertinib-plus-savolitinib-demonstrated-statistically-significant-and-clinically-meaningful-improvements-in-progression-free-and-overall-survival-in-met-driven-egfr-mutated-lung-can\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tagrisso-osimertinib-plus-savolitinib-demonstrated-statistically-significant-and-clinically-meaningful-improvements-in-progression-free-and-overall-survival-in-met-driven-egfr-mutated-lung-can\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260817534800r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260817534800r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tagrisso-osimertinib-plus-savolitinib-demonstrated-statistically-significant-and-clinically-meaningful-improvements-in-progression-free-and-overall-survival-in-met-driven-egfr-mutated-lung-can\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"TAGRISSO\u00ae (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/995812","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=995812"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/995812\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=995812"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=995812"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=995812"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}